Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497431 · ClinicalTrials.gov registry record · Phase 1
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT01497431: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01497431 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01497431, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects and the best dose of Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Se-methyl-seleno-L-cysteine or selenomethionine, two different types of selenium compounds, may prevent prostate cancer from forming.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DIETARY_SUPPLEMENT Selenium
- DRUG Methylselenocysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497431
The ClinicalTrials.gov registry entry for NCT01497431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01497431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497431 about?
NCT01497431 is a clinical study titled "Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants". This randomized phase I trial studies the side effects and the best dose of Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Se-methyl-seleno-L-cysteine or seleno...
What is the current status of trial NCT01497431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2011-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01497431?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Selenium (DIETARY_SUPPLEMENT), Methylselenocysteine (DRUG).
Who is sponsoring clinical trial NCT01497431?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.